Awaiting development: Guidance and quality standards

Showing 61 to 70 of 326

Guidance and quality standards awaiting development
Title	Type
Daratumumab in combination for untreated multiple myeloma when high-dose chemotherapy and autologous stem cell transplant are suitable ID6249	Technology appraisal guidance
Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer TSID 12045	Technology appraisal guidance
Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]	Technology appraisal guidance
Depemokimab for treating chronic rhinosinusitis with nasal polyps ID 6449	Technology appraisal guidance
Depemokimab for treating severe eosinophilic asthma in people 12 years and over ID6447	Technology appraisal guidance
Dersimelagon for treating erythropoietic protoporphyria and X-linked protoporphyria in people 12 years and over TS ID 10392	Technology appraisal guidance
Deucravacitinib for treating active psoriatic arthritis TS ID 11981	Technology appraisal guidance
Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery ID1154	Technology appraisal guidance
Digital platforms for community based self-management of mild to moderate osteoarthritis and joint pain	Medical technologies guidance
Digital platforms to support cardiac rehabilitation	Medical technologies guidance